<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129555">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02055976</url>
  </required_header>
  <id_info>
    <org_study_id>B1481036</org_study_id>
    <nct_id>NCT02055976</nct_id>
  </id_info>
  <brief_title>Dose Ranging Study Of PF-04950615 In Hypercholesterolemic Japanese Subjects</brief_title>
  <official_title>A Phase 2 Double Blind, Parallel Group, Placebo Controlled, Randomized, Dose Ranging Study To Assess The Efficacy, Safety And Tolerability Of PF-04950615 Following Twice Monthly Subcutaneous Doses In Hypercholesterolemic Japanese Subjects Who Are Receiving A Stable Dose Of Atorvastatin Or Treatment Naïve</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the low density lipoprotein cholesterol (LDL-C)
      lowering effect of PF-04950615 administered subcutaneously at every two weeks (Q14D) in
      hypercholesterolemic Japanese subjects whose LDL-C is not controlled by a stable dose of
      atorvastatin, or who are naïve to a treatment by lipid lowering drug and whose LDL-C is not
      controlled.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percent Change from Baseline in LDL-C at Week 12 and 16</measure>
    <time_frame>Week 12 and 16</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Actual Value and Change from Baseline in LDL-C</measure>
    <time_frame>Baseline, Week 12 and 16</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Actual Value, Change from Baseline and Percent Change from Baseline in Lipid parameters</measure>
    <time_frame>Baseline, Week 12 and 16</time_frame>
    <safety_issue>No</safety_issue>
    <description>Total Cholesterol (TC), ApoB, ApoA-I, ApoA-II, Lp(a), High Density Lipoprotein Cholesterol, VLDL-C, Triglyceride, Non-HDL-cholesterol, TC/HDL-C ratio and ApoB/ApoA-I ratio.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects having LDL-C less than particular limits (&lt;100 mg/dL, &lt;70 mg/dL, &lt;40 mg/dL, &lt;25 mg/dL, &lt;10 mg/dL)</measure>
    <time_frame>Week 12 and 16</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug antibody (ADA)</measure>
    <time_frame>Week 24</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC)</measure>
    <time_frame>Week 20</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Week 20</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Observed Plasma Trough Concentration (Cmin)</measure>
    <time_frame>Week 20</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>Week 20</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-Life (t1/2)</measure>
    <time_frame>Week 20</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of PCSK9</measure>
    <time_frame>Week 20</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">216</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Population A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A total of 9 groups in two population. Population A comprises hypercholesterolemic Japanese subjects whose LDL-C is not controlled by a stable dose of atorvastatin. A subject who is receiving a stable dose of atorvastatin will be randomized into one out of 5 dose groups.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Population B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A total of 9 groups in two population. Population B comprises hypercholesterolemic Japanese subjects who are naïve for a treatment by lipid lowering drug and whose fasting LDL-cholesterol is not controlled. A subject who is treatment naïve will be randomized into one out of 4 dose groups.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04950615</intervention_name>
    <description>Atorvastatin plus PF-04950615 50 mg subcutaneous administration at every two weeks (Q14D SC) for 16 week</description>
    <arm_group_label>Population A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04950615</intervention_name>
    <description>Atorvastatin plus PF-04950615 100 mg Q14D SC for 16 week</description>
    <arm_group_label>Population A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04950615</intervention_name>
    <description>Atorvastatin plus PF-04950615 150 mg Q14D SC for 16 week</description>
    <arm_group_label>Population A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Atorvastatin plus PF-04950615 Placebo Q14D SC for 16 week</description>
    <arm_group_label>Population A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe</intervention_name>
    <description>Atorvastatin plus Ezetimibe 10 mg oral administration once daily for 16 week (open)</description>
    <arm_group_label>Population A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04950615</intervention_name>
    <description>PF-04950615 50 mg Q14D SC for 16 week</description>
    <arm_group_label>Population B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04950615</intervention_name>
    <description>PF-04950615 100 mg Q14D SC for 16 week</description>
    <arm_group_label>Population B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04950615</intervention_name>
    <description>PF-04950615 150 mg Q14D SC for 16 week</description>
    <arm_group_label>Population B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>PF-04950615 Placebo Q14D SC for 16 week</description>
    <arm_group_label>Population B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects whose LDL-C is not controlled by a stable dose of atorvastatin (Population
             A).

          -  Subjects who are naïve to a treatment by lipid lowering drug and whose LDL-C is not
             controlled (Population B).

        Exclusion Criteria:

          -  Severe acute or chronic medical or psychiatric condition or laboratory abnormality.

          -  Pregnant females; breastfeeding females; males and females of childbearing potential;
             males and females of childbearing potential who are unwilling or unable to use a
             highly effective method of contraception.

          -  Subjects who were administered or prior exposed to PF-04950615 and/or anti-body
             targeting PCSK9.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Maebashi</city>
        <state>Gunma</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chiyoda-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Toshima-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1481036&amp;StudyName=Dose%20Ranging%20Study%20Of%20PF-04950615%20In%20Hypercholesterolemic%20Japanese%20Subjects</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 14, 2014</lastchanged_date>
  <firstreceived_date>January 22, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PF-04950615</keyword>
  <keyword>Japan</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atorvastatin</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
